SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace HotelGlobeNewsWire • 10/19/22
Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial PneumoniGlobeNewsWire • 10/12/22
Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory StimulantGlobeNewsWire • 10/03/22
Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (“IM”) Formulation of ENA-001GlobeNewsWire • 09/27/22
Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 08/30/22
Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin LitigationGlobeNewsWire • 08/18/22
Eagle Pharmaceuticals, Inc's (EGRX) CEO Scott Tarriff on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag EstimatesZacks Investment Research • 08/09/22
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory StimulantGlobeNewsWire • 08/09/22
Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care FootprintGlobeNewsWire • 06/09/22
Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic BlockerGlobeNewsWire • 06/01/22
Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock ConferenceGlobeNewsWire • 05/26/22
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022GlobeNewsWire • 04/28/22
Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028GlobeNewsWire • 04/19/22
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 04/11/22
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/07/22
Eagle Pharmaceuticals (EGRX) Lags Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/07/22